| Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635) |
|---|
| 02/26/2002 | US6350446 Polypeptides with amino acid sequences for kidney failure |
| 02/26/2002 | CA2206776C N-sulfonylindoline derivatives carrying an amide functional group, their preparation and the pharmaceutical compositions in which they are present |
| 02/26/2002 | CA2160966C Piperidine derivatives; process for preparing them and compositions containing the same |
| 02/21/2002 | WO2002014485A2 Kallikrein gene |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |
| 02/21/2002 | WO2002014348A2 Glycoproteins and methods of use thereof |
| 02/21/2002 | WO2002014347A2 Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts |
| 02/21/2002 | WO2002014285A1 Substituted imidazoles as tafia inhibitors |
| 02/21/2002 | WO2002014279A1 New aporphine esters and their use in therapy |
| 02/21/2002 | WO2002013982A1 Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
| 02/21/2002 | WO2002013839A1 Animal papilla disinfectants and method of improving microbial environment |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001058910A3 Lipid-based drug delivery systems |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2001028516A3 Sustained-release formulations for treating cns-mediated disorders |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | US20020022816 Device |
| 02/21/2002 | US20020022640 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 02/21/2002 | US20020022625 Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments |
| 02/21/2002 | US20020022619 Administering to the mammal suffering from anxiety, depression and other disorders related to excessive corticotropin releasing factor an effective amount of tricyclic pyridine or pyrimidine derivatives |
| 02/21/2002 | US20020022609 Orally active androgens |
| 02/21/2002 | US20020022600 Azt derivatives exhibiting spermicidal and anti-viral activity |
| 02/21/2002 | US20020022254 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | DE10039199A1 Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen Combination preparations of ERß a selective estrogen and a SERM or antiestrogen |
| 02/21/2002 | CA2418240A1 A disinfectant for teats of animals, and a method for improving microorganism-enviroment harmful for animals |
| 02/21/2002 | CA2417141A1 Novel glycoproteins and methods of use thereof |
| 02/20/2002 | EP1180032A2 Use of nicorandil in treatment of sexual dysfunctions or for enhancement of sexual functions |
| 02/20/2002 | EP1180021A1 Regimen and kit for amelioration of premature ejaculation |
| 02/20/2002 | EP0772441B1 Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri |
| 02/20/2002 | EP0719137B1 Viscous surfactant emulsion compositions |
| 02/20/2002 | CN1336935A Compositions and methods for WT1 specific immunotherapy |
| 02/20/2002 | CN1336926A Carbamate derivatives of diaryl 1,3,4-oxadiazolone |
| 02/20/2002 | CN1336924A Amide and urea derivatives as 5-HT reuptake inhibitors and at 5-HT 1B/1D ligands |
| 02/20/2002 | CN1336919A Phenylphenanthridines with PDE-IV inhibiting activity |
| 02/20/2002 | CN1336381A Trichosanthin mutant and its prepn. |
| 02/20/2002 | CN1336219A Gynopathy treating traditional Chinese medicine |
| 02/20/2002 | CN1336184A Baichun Prepn. for treating women's pelvic infection |
| 02/20/2002 | CN1336173A Chinese medicine spray for treating vaginal relaxation |
| 02/20/2002 | CN1079262C Traditional Chinese medicine for treating aciesis of man or women and its prepn. method |
| 02/20/2002 | CN1079242C Health-care medicinal liquor and its prepn. method |
| 02/20/2002 | CN1079232C Unitary vaginal dosage, and its prepn. method |
| 02/19/2002 | USRE37556 Superoxide radical inhibitor |
| 02/19/2002 | US6348602 Cyclic AMP-specific phosphodiesterase inhibitors |
| 02/19/2002 | US6348500 Increasing the sperm count in males |
| 02/19/2002 | US6348213 Intravenously administering liposomes having lipid component comprising phosphatidylcholine having same acyl chains as phosphatidylcholines in heart cells of younger subjects, repeating until drop in serum creatine phosphokinase is noted |
| 02/14/2002 | WO2002012537A2 Mutant trichosanthin |
| 02/14/2002 | WO2002012341A2 Her-2/neu fusion proteins |
| 02/14/2002 | WO2002012340A2 Transporters and ion channels |
| 02/14/2002 | WO2002012330A2 Human secreted protein, zzp1 |
| 02/14/2002 | WO2002012246A1 Pyrrolotriazolopyrimidinone derivatives |
| 02/14/2002 | WO2002012228A1 Cinnoline compounds |
| 02/14/2002 | WO2002012227A2 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 02/14/2002 | WO2002012226A1 Quinoline derivatives having vegf inhibiting activity |
| 02/14/2002 | WO2002012192A1 Quinolene derivatives as anti-inflammation agents |
| 02/14/2002 | WO2002012178A1 Compounds acting as melanocortin receptor ligands |
| 02/14/2002 | WO2002011765A1 COMBINATION PREPARATION WITH AN ERβ SELECTIVE ESTROGEN AND A SERM OR ANTIESTROGEN |
| 02/14/2002 | WO2002011742A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 02/14/2002 | WO2002011735A2 Association of a purine activity and a nonsteroidal anti-inflammatory anti-inflammatory drug for treating sexual dysfunction |
| 02/14/2002 | WO2002011715A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | WO2002011714A2 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | WO2002011706A2 Drugs for sex dysfunctions |
| 02/14/2002 | WO2002011705A2 Composition for combined use of aromatase inhibitors |
| 02/14/2002 | WO2002011665A2 Association of a purine and a nonsteroidal anti-inflammatory drug for treating sexual dysfunction |
| 02/14/2002 | WO2001068603A3 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 02/14/2002 | WO2001056598A3 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
| 02/14/2002 | WO2001055119A3 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 02/14/2002 | WO2001049685A3 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 02/14/2002 | WO2001048161A3 Human heparanase-related polypeptide and nucleic acid |
| 02/14/2002 | WO2001044502A3 Genetic variants of the human fsh receptor and the influence thereof on gametogenesis |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001041807A3 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019523 Dietetics; antidabetic agents; sexual disrders |
| 02/14/2002 | US20020019411 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 02/14/2002 | US20020019396 Pharmaceutically active morpholinol |
| 02/14/2002 | US20020018752 Ablation disease by cutting, blocking blood supply to tissue |
| 02/14/2002 | CA2420066A1 Use, in combination, of a purine activity and a nonsteroidal anti-inflammatory drug for preparing an anti-thrombotic and/or anti-inflammatory drug |
| 02/14/2002 | CA2419042A1 Medicine for fighting against sexual dysfunction |
| 02/14/2002 | CA2418951A1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | CA2418832A1 Quinolene derivatives as anti-inflammation agents |
| 02/14/2002 | CA2417915A1 Her-2/neu fusion proteins |
| 02/14/2002 | CA2417784A1 Pyrrolotriazolopyrimidinone derivatives |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | CA2416525A1 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415469A1 Quinoline derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415022A1 Cinnoline compounds |
| 02/13/2002 | EP1179066A2 Extracellular signaling molecules |
| 02/13/2002 | EP1179005A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
| 02/13/2002 | EP1178993A1 Thiazoloderiatives and pharmaceutical compositions containing them |
| 02/13/2002 | EP1178984A2 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/13/2002 | EP1178977A1 Ion channel modulating agents |
| 02/13/2002 | EP1178973A2 Novel compounds, their use and preparation |
| 02/13/2002 | EP1178963A1 Ion channel modulating agents |
| 02/13/2002 | EP1178962A1 Process for the preparation of paroxetine acetate and analogues thereof |
| 02/13/2002 | EP1178833A1 Topical compositions for prostaglandin e 1? delivery |
| 02/13/2002 | EP1178812A2 Conditioned cell culture medium compositions and methods of use |